Changing from lipoprotein apheresis to evolocumab treatment lowers circulating levels of arachidonic acid and oxylipins.
Wang C, Kaufmann A, Kampschulte N, Elbelt U, Kassner U, Steinhagen-Thiessen E, Pietzner A, Schmöcker C, Datta D, Sanpietro T, Schebb NH, Weylandt KH, Rohwer N.
Wang C, et al. Among authors: kassner u.
Atheroscler Plus. 2024 Feb 12;55:55-62. doi: 10.1016/j.athplu.2024.01.005. eCollection 2024 Mar.
Atheroscler Plus. 2024.
PMID: 38390468
Free PMC article.